CHHiP is a phase 3 trial of hypofractionated versus conventional radiotherapy for localized prostate cancer
The trial previously demonstrated the noninferiority of hypofractionated high-dose intensity-modulated radiotherapy to the conventional procedure in men with localized prostate cancer.
Long-term data from the CHHiP trial, presented at ASCO GU 2020 by Dr David Dearnaley (The Institute of Cancer Research, UK), further support hypofractionated radiotherapy for prostate cancer.